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Dresden, GermanyCarney complex is a rare genetic disorder that was first
described by Carney and colleagues1 in 1985. It is mainly
characterized by cardiac myxoma, spotty pigmentation
and endocrine hyperactivity. In approximately 50% of the
affected patients, a heterozygous mutation of the protein
kinase A regulatory subunit 1 gene (PRKAR1A) can be
found. The mutation, which is usually localized on the
long arm of chromosome 17 (17q22–q24), is named
CC-Type 1. In CC-Type 2, the mutation can be found on
chromosome 2 (2p16). The heredity is autosomal dominant
with variable penetrance. There exist no clinical differences
between genetic carriers and noncarriers.2CLINICAL SUMMARY
In 2012, a 60-year-old female patient with Carney
complex and history of previous 4 cardiac operations for
recurrent myxoma was seen for elective echocardiographic
control. The previous control by magnetic resonance
imaging (MRI) 5 months previously had been unremarkable
(Figure 1, A).
In 1988, 1991, 2002, and 2008 she had already undergone
cardiac surgery for resection of cardiac myxoma at different
localizations. Further clinical signs of Carney complex
were recurrent mucosal tumors since her earliest childhood,
spotty pigmentation, hirsutism, syndactyly of the toes,
kyphosis, hyperthyroidism, and an adenoma of the pituitary
gland. The patient also had a history of peripheral arterialembolism and occlusion of superficial femoral artery. As
demonstrated in the family tree in Figure 2, the patient
was the only one in her family affected by clinical signs
of Carney complex. Genetic examination of her family
has not been performed to date.
MRI and echocardiography revealed a new intracardiac
tumor-formation in the left ventricle affecting the mitral
annulus (Figure 1, A–C). Cardiac surgery was performed
through a median sternotomy and with common aortic can-
nulation. For venous cannulation, a 2-stage cannula was
used. The procedure was performed in normothermia. Intra-
operatively, the myxoma was resected (Figure 1, D).
Because of the involvement of the mitral annulus and
the need for radical resection, biologic mitral valve
replacement was also performed. The intraoperative and
postoperative courses were uneventful. Predischarge
echocardiography revealed good prosthetic function.
Histopathologic examination identified the tumor as a
myxoma. The patient was dismissed from the hospital on
postoperative day 6.
DISCUSSION
Carney complex is a rare genetic disorder.1,3 This patient
demonstrated all the typical signs of Carney complex
including myxoma, spotty pigmentation, endocrine
hyperactivity, and cutaneous tumors. As is typical with
complications of cardiac tumors, the patient also had a
history of peripheral arterial embolism and occlusion of
superficial femoral artery. In contrast with other reported
cases, a specific characteristic of the present case was the
fifth recurrence of myxoma, each time at a different
location.4,5 The reported patient is the sole person
affected by Carney complex in her family. This might be
explained by the variable penetrance of the autosomal
dominant genetic disorder. Her fifth reoperative cardiac
surgical procedure could be performed without any
procedural morbidity, despite strong pericardial
adhesions. Worth mentioning is the fact that MRI controlery c October 2013
FIGURE 1. A, Magnetic resonance imaging scan of the heart demonstrating left ventricular tumor (arrow) in August 2012. Previous control scan in March
2012 (inset) was unremarkable. B and C, Transesophageal echocardiography revealing the left-ventricular tumor (asterisk). D, Intraoperative photograph of
resected specimen.
Case Reportsonly 5 months before had been unremarkable, which
highlights the need for control examinations at close
intervals. Common diagnostic modes, such as clinical
examination, electrocardiography, and chest radiography,FIGURE 2. Family t
The Journal of Thoracic and Caare inefficient. Further diagnostic modes, such as
transesophageal echocardiography or MRI scan, are
required. Identification and close monitoring of patients
with recurrent myxoma in the context of Carney complexree of the patient.
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Case Reportsis of utmost importance to prevent such typical
complications of cardiac tumors as stroke or embolism.
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The St Jude Medical Portico THV (St Jude Medical, Inc,
St Paul, Minn) is the first fully resheathable percutaneous
valve. We report the feasibility of implantation of the
23-mm St Jude Medical Portico THV by the transapical
approach. Despite this encouraging initial experience,
future studies are needed to demonstrate the safety and
efficacy of this new valve.
CLINICAL SUMMARY
An 82-year-old woman was referred to our center for
aortic valve replacement. She was not considered to be a
candidate for surgical aortic valve replacement in the eval-
uation of the heart team because of severe comorbidities
(diabetes, hypertension, anemia, recent myocardial infarc-
tion requiring percutaneous intervention with left main
drug eluting stent implantation, severe peripheral vascular
disease) leading to a predicted risk of perioperative mor-
tality of 7.8 as estimated by Society of Thoracic Surgeonsscore. An echocardiographic assessment confirmed a
severely calcific aortic stenosis (mean gradient 38 mm
Hg; aortic valve area: 0.65 cm2) with normal left ventric-
ular function and an aortic annulus of 19.5 mm. A trans-
catheter aortic valve implantation procedure with the 23-
mm Portico valve through the transapical approach was
planned. Signed, informed consent was obtained for the
procedure and for this publication.
The procedure was performed in the operating room
with general anesthesia and echocardiographic and fluoro-
scopic guidance with a C-arm radiographic system. A
standard transapical approach was carried out, as
described previously.1 Initially, a 7F sheath was inserted
to secure the access site. After a stiff wire was placed in
the descending aorta, the 7F sheath was replaced by a
14F introducer sheath. An aortic valvuloplasty was then
performed with an 18-mm balloon, after which the 24F
(outer diameter) St Jude delivery system with integrated
sheath and mounted Portico valve was inserted through
the apex and placed at the aortic annulus level on the stiff
wire (Figure 1, A). Rapid pacing was not used for valve
deployment. The valve was gradually released by rotating
the thumbwheel in a clockwise direction with a continuous
tension to keep the position of the distal edge of the skirt
at the level of the aortic annulus (Figure 1, B). When 80%
of the valve had been released, the positioning was as-
sessed with several angiographic studies (Figure 1, C,
and Video 1). The valve was recaptured and repositioned
to achieve an optimal position, at which time it was fully
released (Figure 1, D). Balloon postdilatation with a
23-mm balloon was performed because of initial
mild-to-moderate paravalvular aortic regurgitation (PAR).
After balloon and sheath removal, once hemostasis was
complete, the chest was closed in a standard fashion.
The final result showed trivial PAR and correct positioningery c October 2013
